Latest Administration News

VanEck Investments Limited has released an updated Product Disclosure Statement detailing seven Australian fixed income ETFs listed on the ASX, offering investors diversified exposure across government bonds, corporate debt, and subordinated securities.

JAYRIDE Group Limited has raised $935,000 through a share placement and convertible notes, signaling strong shareholder confidence as it advances toward ASX reinstatement and regional SaaS growth.

Imagion Biosystems is set to submit its Investigational New Drug application for the MagSense® HER2 breast cancer imaging agent in December 2025, paving the way for a Phase 2 clinical trial in early 2026. Collaboration with Wayne State University has refined the trial design, promising improved patient safety and diagnostic precision.

InvestSMART Funds Management has updated the Distribution Reinvestment Plan rules for its Intelligent Investor Active ETFs, making DRP participation automatic for new investors from January 2026 unless they opt out.

C29 Metals has explained a delayed filing of a director interest notice as an isolated administrative oversight, reaffirming its compliance policies.

DGL Group reported a modest revenue increase in FY25 but faced a sharp decline in profitability, compounded by an auditor’s disclaimer and ERP rollout delays impacting FY26 start.

Singular Health has submitted a 510(k) premarket notification to the FDA for its enhanced 3DICOM MD Cloud platform, aiming to expand imaging capabilities and introduce a scalable, cloud-native solution for medical image management.

Cann Group Limited has announced a dramatic 81% reduction in core debt alongside a strategic pivot to higher-margin flower products, positioning the company for its first EBITDA-positive year in FY26.

European Metals Holdings has been awarded a substantial grant of up to €360 million by the Czech Government to advance its Cinovec Lithium Project, underscoring the project's strategic importance in Europe's clean energy transition.

Gale Pacific’s FY25 results reveal a challenging year marked by tariff disruptions in the Americas, prompting a strategic overhaul of its US operations to safeguard future growth.

TruScreen Group Limited reported a 17% decline in first half FY2026 product sales but affirmed full-year revenue guidance at NZ$2.8 million, supported by strategic expansions and a successful NZ$4 million capital raise.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.